STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #517 by analyst upside · 2026-08-14
QTTB
Q32 Bio Inc.
Healthcare · Market Cap $458M · P/E 4.9x
ANALYST PRICE TARGET
+178.1%
implied upside to consensus target
Current Price $15.37
Consensus Target $42.75
Bull Target $59.0
Bear Target $36.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
0
Sell
0
52-Week Low $1.62
52-Week High $23.57
YTD Return +346.8%
FUNDAMENTALS
Market Cap $458M
P/E Ratio (TTM) 4.9x
Forward P/E N/A
EPS (TTM) $3.14
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $54M
Profit Margin 62.9%
52-WEEK RANGE
52-Week Low $1.62
52-Week High $23.57
Current Price $15.37
Bear Target $36.0
Bull Target $59.0
● Now $15.37 ● Target $42.75
TRADING DATA
Avg Volume 1.5M
YTD Return +346.8%
Analyst Count 4
Consensus Buy
Upside to Target +178.1%
Last Updated 2026-08-14

ANALYST SUMMARY

Q32 Bio Inc. (QTTB) is currently trading at $15.37 with a Wall Street consensus price target of $42.75, implying potential upside of 178.1% over the next 12 months. 4 analysts currently cover QTTB, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $59.0, while the most cautious has a target of $36.0.

QTTB operates in the Healthcare sector with a market capitalisation of $458M. The stock is up 346.8% year-to-date and is currently trading near the upper end of its 52-week range of $1.62 – $23.57.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for QTTB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Mizuho ● Initiated
Outperform 2026-05-22 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2026-05-18 40% win rate (10 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-05-05 31% win rate (48 calls)
HC Wainwright & Co. ● Initiated
Buy 2026-02-25 31% win rate (48 calls)
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2025-03-12 Building track record
BMO Capital ↓ Downgrade
Outperform → Market Perform 2025-02-11 Building track record
Piper Sandler ↓ Downgrade
Overweight → Neutral 2025-02-11 14% win rate (7 calls)
BMO Capital - Reiterated
Outperform → Outperform 2024-12-12 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
39
out of 100
Coverage depth
12/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →